Also disclosed is the use of: (i) an antibody or an antigen binding fragment thereof specific for at least one epitope of Hsp90; and (ii) at least one anti-cancer agent selected from the group consisting of Imatinib, Paclitaxel, Docetaxel, Daunorubicin, Doxorubicin, and Hydroxyurea in the ...
These data suggest that a chimeric kappa light chain antibody could be potentially used as an anti-cancer agent, thereby introducing a novel type of antibody fragment, with reduced possible adverse immunogenic effects, into cancer therapeutics. 展开 ...
MDA-MB-453 cells into the lungs of SCID mice. These data suggest that a chimeric kappa light chain antibody could be potentially used as an anti-cancer agent, thereby introducing a novel type of antibody fragment, with reduced possible adverse immunogenic effects, into cancer therapeutics. ...
Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A), and stimulates Il1a trans... Gamendazole was recently identified as an orally active antispermatogenic compound with antifertility effects. The cellular mechanism(s)...
Oncogenic client-proteins of the chaperone Heat shock protein 90 (HSP90) insure unlimited tumor growth and are involved in resistance to chemo- and radiotherapy. The HSP90 inhibitor Onalespib initiates the degradation of oncoproteins, and might also act
The present invention relates to 1,2,4-triazole derivatives newly separated by Hsp90 inhibitors, and the compounds of the present invention can be used in anticancer composition targeting Hsp90.;Hsp90, anticancer agent, 1,2,4-triazoleHAHN, JI SOOK...
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 Heat shock protein 90 (Hsp90) is an emerging therapeutic target of interest for the treatment of cancer. Its role in protein homeostasis and the selective ... ...
Disclosed is a substance which is not accumulated stably in cells, does not cause the dysfunction of normal cells, and so on, and therefore can be used as an anti-cancer agent or in a DDS without having any adverse side effects. It is found that Hsp90 alone cannot exhibit its function ...
156 POSTER BIIB021, a fully synthetic oral small molecule inhibitor of Hsp90, shows potent anti-tumor activity as a single agent and in combination with st... Inhibition of heat shock protein 90 (Hsp90) results in the degradation of oncoproteins that drive malignant progression, inducing cell...
significantly reverse tauopath纬-induced cognitive impairment.Overall,this work takes advantage of the combination of intracellular and extracellular regulatory strategies targeting tau hyperphosphorylation,providing a promising and efficient therapeutic candidate agent for AD and other tau-related neurodegenerative...